OVERVIEW
Celltrion Pharm’s Growth Knows No End
Celltrion Pharm’s growth continues, along with its efforts for a better future
Prescribed hepatotonic
medicine in Korea
Godex Cap. ranked 1st
among Korean hepatotonics
in outpatient prescription
(as of 2025)
Oral solid manufacturing
facility to obtain
GMP certification
Cheongju Plant obtained
the first American and
EuropeanGMP approval
among Korean oral solid
manufacturing facilities.
Worth of Remsima
sold in Korea
The domestic cumulative
sales of Remsima,
world’s first
antibody biosimilar,
exceeded KRW 300.8 billion
(as of December 2025)
Biopharmaceutical
products in Korea
Celltrion Pharm holds exclusive domestic sales rights for various biopharmaceuticals, including Remsima, Truxima, Herzuma, Remsima SC, Yuflyma, Vegzelma, Eydenzelt, Omlyclo, Steqeyma, Stoboclo, Osenvelt and Avtozma Korea
In revenue
(as of 2025)
Employees
(as of December 2025)